JUN 0 5 2006 BY TRADEMARKOW

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICATION NUMBER:

10/664,639

FILING DATE:

September 18, 2003

FIRST NAMED INVENTOR:

Timothy Vickers

ART UNIT:

1634

EXAMINER NAME:

ATTORNEY DOCKET NUMBER:

CORE0027US

TITLE:

EFFICIENT REDUCTION OF TARGET

RNA's BY SINGLE- AND DOUBLE-STRANDED OLIGOMERIC

COMPOUNDS

I certify that this communication is being deposited with the U.S. Postal Service as First Class Mail in an envelope addressed to Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below:

Dated: <u>May 30, 2006</u>

Pamela Grooms

MAIL STOP AMENDMENT COMMISSIONER FOR PATENTS P.O. BOX 1450 ALEXANDRIA, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT Under 37 C.F.R. §§ 1.56 and 1.97-98

SIR:

Pursuant to the provisions of 37 C.F. R. §§ 1.56 and 1.97-98, enclosed herewith is PTO Form PTO/SB/08A and PTO/SB/08B listing references for consideration by the Examiner.

The filing of this Information Disclosure Statement shall not be construed as a representation regarding the completeness of the list of references, or that inclusion of a reference in this list is an admission that it is prior art or is pertinent to this application, or that a search has been made, or as an admission that the information listed is, or may be considered to be, material to patentability, or that no other material information exists, and shall not be construed as an admission against interest in any manner.

This Information Disclosure Statement is being filed:

Serial No.: 10/664,639 Docket No.: CORE0027US

within three months of the filing date of the application, or date of entry
into the national stage of an international application, or before the mailing
date of a first office action on the merits, whichever event last occurred;
before the mailing of a first official action after filing of a request for
continued examination (RCE) under 37 C.F.R. § 1.114;
after three months of the filing date of this national application or the date
of entry of the national stage in an international application, or after the
mailing date of the first official action on the merits, whichever event last
occurred, but before that mailing date of the first office action to occur of
either: (1) a final action under 37 C.F.R. § 1.113; or (2) an action that
otherwise closes prosecution in the application, and:
attached hereto is the fee set forth under 37 C.F.R. § 1.17(p) for
submission of this Information Disclosure Statement under 37 C.F.R.
1.97(c); OR
Applicant certifies pursuant to 37 C.F.R. § 1.97(e) that:
each item of the information contained in this Information
Disclosure Statement was first cited in a communication from a
foreign patent office in a counterpart foreign application not
more than three months prior to the filing of this Statement;
OR
no item of information contained in this Information
Disclosure Statement was cited in a counterpart foreign
application and, to the knowledge of the person signing this
certification after making reasonable inquiry, no item of
information contained in this Statement was known to any
individual designated under 37 C.F.R. § 1.56(c) more than three
months prior to the filing of this Statement.
on or before the payment of the issue fee but after the mailing date of the
first to occur of either: (1) a final action under 37 C.F.R. § 1.113; (2) a notice
of allowance under 37 C.F.R. § 1.311; or (3) an action that otherwise closes
prosecution in the application, and:
Applicant certifies pursuant to 37 C.F.R. § 1.97(e) that:
each item of information contained in this Information
Disclosure Statement was cited in a communication from a

foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement; OR no item of information contained in this Information Disclosure Statement was cited in a counterpart foreign application and, to the knowledge of the person signing this certification after making reasonable inquiry, no item of information contained in this Statement was known to any individual designated under 37 C.F.R. § 1.56(c) more than three months prior to the filing of this Statement. AND attached hereto is the fee set forth under 37 C.F.R. § 1.17(p) for submission of this Information Disclosure Statement under 37 C.F.R. § 1.97(c); OR after the payment of the issue fee. Applicant requests that the information contained in this Information Disclosure Statement be placed in the file according to 37 C.F.R. § 1.97(i), although the information may not be considered by the USPTO. Enclosed is a copy of each listed reference that may be material to the examination of this application, and for which there may be a duty to disclose. This application relies, under 35 U.S.C. § 120, on the earlier filing date of prior application No. , filed on , and the references cited therein are hereby referenced, but are not required to be provided in this application under 37 C.F.R. § 1.98(d). This application was filed after June 30, 2003. Therefore, pursuant to the waiver of the requirements under 37 C.F.R. § 1.98(a)(2)(i), copies of each U.S. Patent and each U.S. Patent Application Publication are not required to be submitted. Copies of any foreign patent documents and non-patent literature cited herein are enclosed. Each item of information contained in this Information Disclosure Statement was cited in the communication from a foreign patent office in a counterpart application, and the communication was not received by any individual designated in 37 C.F.R. § 1.56(c) more than thirty days prior to the filing of this Information Disclosure Statement 37 C.F.R. § 1.704(d).

Serial No.: 10/664,639 Docket No.: CORE0027US

Applicant submits that no fee is required for the consideration of this Information Disclosure Statement. However, if a fee is due, the Commissioner is hereby authorized to charge Deposit Account No 500252 referencing case number CORE0027US.

Consideration of the listed references and favorable action are solicited.

Respectively Submitted,

Dated:

Jodi L. Connolly, Ph.D. Registration No.: 54,044

Isis Pharmaceuticals, Inc. 1896 Rutherford Road Carlsbad, CA 92008

PTO/SB/08a (08-03)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitu	te for form 1449A/PT	0		Complete if Known			
				Application Number	10/664,639		
INFO	DRMATION	DIS	CLOSURE	Filing Date	Sept. 18, 2003		
STATEMENT BY APPLICANT				First Named Inventor	Timothy Vickers		
				Art Unit	1634		
(Use as many sheets as necessary)			necessary)	Examiner Name			
Sheet	1	of	2	Attorney Docket Number	CORF0027US		

			U.S. PATENT I	OCUMENTS		
Examiner	Cite No.1	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevan	
Initials *		Number - Kind Code ² (if known)			Passages or Relevant Figures Appear	
	CF	5,670,633	09/23/1997	Isis Pharmaceuticals, Inc.		
	CG	5,898,031	04/27/1999	Isis Pharmaceuticals, Inc.		
	СН	6,005,087	12/21/1999	Isis Pharmaceuticals, Inc.		
	CI	6,107,094	08/22/2000	Isis Pharmaceuticals, Inc.		
	Cl	6,172,216	01/09/2001	Isis Pharmaceuticals, Inc.		
	СК	6,210,892	04/03/2001	Isis Pharmaceuticals, Inc.		
	CL	6,476,205	11/05/2002	Isis Pharmaceuticals, Inc.		
	CM	6,531,584	03/11/2003	Isis Pharmaceuticals, Inc.		
	CN	US 2002-0049173	04/25/2002	Isis Pharmaceuticals, Inc.		
	co	US 2002-0165189	11/7/2002	Isis Pharmaceuticals, Inc.		
	CP	US 2003-0004325	01/02/2003	Isis Pharmaceuticals, Inc.		
	CQ	US 2003-0096784	05/22/2003	Isis Pharmaceuticals, Inc.		
	CR	US 2003-0119777	06/26/2003	Isis Pharmaceuticals, Inc.		

FOREIGN PATENT DOCUMENTS									
Examiner Initials*	Cite	Foreign Patent Document	Publication	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear				
	No.1	Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)	Date MM-DD-YYYY			T ⁶			
	cs	WO 2004/097049	11/11/2006	Isis Pharmaceuticals, Inc.					
<u> </u>									

Examiner Signature	Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. If if possible. Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2

Substitute	for form 1449B/PT0)			Complete if Known	
INICO	DRAKTION	DIO	OL COURT	Application Number	10/664,639	
			CLOSURE	Filing Date	09/18/2003	
STATEMENT BY APPLICANT				First Named Inventor	Timothy Vickers	
				Art Unit	1634	
(Use as many sheets as necessary)			necessary)	Examiner Name		
Sheet	2	of	2	Attorney Docket Number	CORE0027US	

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T 2
	СТ	Brown-Driver et al., "Inhibition of Translation of Hepatitis C Virus RNA by 2'-Modified Antisense Oligonucleotides," Antisense Nucleic Acid Drug Dev. (1999) 9(2): 145-154	
	CU	Wu et al., "Integrin-linked Protein Kinase Regulates Fibronectin Matrix Assembly, Ecadherin Expression, and Tumorigenicity," <i>J. Biol. Chem.</i> (1998) 273(5):2532-2542	
			<u> </u>
		•	

Examiner	Date	1	
Signature	Considered		

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademank Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.